Pentostatin and purine analogs for indolent lymphoid malignancies

Future Oncology

Volumn 2, Issue 2, 2006, Pages 169-183

  Ho, Anthony D ^a   Hensel, Manfred ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic lymphocytic leukemia; Graft versus host disease; Hairy cell leukemia; Low grade lymphomas; Lymphoplasmacytic lymphomas; Lymphoproliferative diseases; Pentostatin (2 deoxycoformycin); Purine degradative enzymes

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE; ANTIBODY; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; FLUDARABINE; FLUDARABINE PHOSPHATE; INTERFERON; INTERLEUKIN 2; MELPHALAN; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE; ADENOSINE DEAMINASE; ANTINEOPLASTIC ANTIBIOTIC; PURINE NUCLEOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TOLERANCE; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GRAFT VERSUS HOST REACTION; HAIRY CELL LEUKEMIA; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LOW DRUG DOSE; LUNG TOXICITY; LYMPHATIC LEUKEMIA; LYMPHOCYTOTOXICITY; LYMPHOMA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEPSIS; SEZARY SYNDROME; SKIN LYMPHOMA; SPLENECTOMY; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA; DRUG ANTAGONISM; PROLYMPHOCYTIC LEUKEMIA;

ADENOSINE DEAMINASE; ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; LEUKEMIA, HAIRY CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, PROLYMPHOCYTIC; PENTOSTATIN; PURINE NUCLEOSIDES;

EID: 33646442816     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.2.169     Document Type: Review

References (92)

1. Gandhi V, Plunkett W: Cellular and clinical pharmacology of fludarabine. Clin, Pharmacokinet. 41, 93-103 (2002).
2. Carson DA, Wasson DB, Taetle R, Yu A: Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62, 737-743 (1983).
3. Woo P, Dion H, Lange S, Dahl L, Durham L: A novel adenosine and araA deaminase inhibitor, (R)-3-(2-deoxy-βB-D-Erythro-pento-furanosyl)-3, 6,7,8-tetra-hydroimidazo (4,5-d) (1,3) diazepin-8-ol. J Heterocyclic Chem. 11, 641-643 (1974).
4. Agarwal RP, Spector T, Parks RE: Inhibition of adenosine deaminase by various inhibitors. Biochem. Pharmacol. 26, 359-367 (1977).
5. Ho AD, Knauf W, Ganeshaguru K, Hunstein W, Hoffbrand AV: Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia. Hematol. Oncol. 5, 9-17 (1987).
6. Giblett ER, Anderson JE, Cohen F. Pollara B, Meuwissen HJ: Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2, 1067-1069 (1972).
7. Giblett ER, Ammann AJ, Wara DW, Sandman R, Diamond LK: Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1, 1010-1013 (1975).
8. Biggar WD, Giblett ER, Ozere RL, Grover BD: A new form of nucleoside phosphorylase deficiency in two brothers with defective T-cell function. J. Pediatr. 92, 354-357 (1978).
9. Barton R, Martiniuk F, Hirschhorn R, Goldschneider I: The distribution of adenosine deaminase among lymphocyte populations in the rat. J. Immunol. 122, 216-220 (1979).
10. Chechik BE, Schrader WP, Minowada J: An immunomorphologic study of adenosine deaminase distribution in human thymus tissue, normal lymphocytes, and hematopoietic cell lines. J. Immunol. 126, 1003-1007 (1981).
11. Tung R, Silber R, Quagliata F, Conklyn M, Gottesman J, Hirschhorn R: Adenosine deaminase activity in chronic lymphocytic leukemia. Relationship to B- and T-cell subpopulations. J. Clin. Invest. 57, 756-761 (1976).
12. Ganeshaguru K, Lee N, Llewellin P et al.: Adenosine deaminase concentrations in leukaemia and lymphoma: relation to cell phenotypes. Leuk. Res. 5, 215-222 (1981).
13. Ho AD, Ganeshaguru K: Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors. Klin. Wochenschr. 66, 467-474 (1988).
14. Cohen A, Hirschhorn R, Horowitz SD et al.: Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc. Natl Acad. Sci. USA 75, 472-476 (1978).
15. Hershfield MS, Kredich NM: Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation. Proc. Natl Acad. Sci. USA 77, 4292-4296, (1980).
16. Hershfield MS, Kredich NM, Koller CA et al.: S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2′-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine. Cancer Res. 43, 3451-3458 (1983).
17. Gelfand EW, Lee JJ, Dosch HM: Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proc. Natl Acad. Sci. USA 76, 1998-2002 (1979).
18. Poplack DG, Sallan SE, Rivera G et al.: Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res. 41, 3343-3346 (1981).
19. Prentice HG, Smyth JF, Ganeshaguru K et al.: Remission induction with adenosine-deaminase inhibitor 2′-deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet 2, 170-172 (1980).
20. Prentice HG, Russell NH, Lee N et al.: Therapeutic selectivity of and predication of response to 2′-deoxycoformycin in acute leukaemia. Lancet 2, 1250-1254 (1981).
21. Smyth JF, Paine RM, Jackman AL et al.: The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother: Pharmacol. 5, 93-101 (1980).
22. Grever MR, Siaw MF, Jacob WF et al.: The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57, 406-417 (1981).
23. Greyer MR, Leiby JM, Kraut EH et al.: Low-dose deoxycoformycin In lymphoid malignancy. J. Clin. Oncol. 3, 1196-1201 (1985).
24. Spiers AS, Ruckdeschel JC, Horton J: Effectiveness of pentostatin (2′-deoxycoformycin) in refractory lymphoid neoplasms. Scand. J. Haematol. 32, 130-134 (1984).
25. Ho AD, Thaler J, Stryckmans P et al.: Pentostatin in refractory chronic lymphocytic leukemla: a Phase II trial of the European Organization for Research and Treatment of Cancer. J.Natl Cancer Inst. 82, 1416-1420 (1990).
26. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA: Mechanism of deoxyadenosine and 2-lorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest. 75, 377-383 (1985).
27. Ho AD, Ganeshaguru K, Knauf WU et al.: Clinical response to deoxycoformycin in chronic lymphoid neoplasms and biochemical changes in circulating malignant cells in vivo. Blood 72, 1884-1890 (1988).
28. Siaw MF, Coleman MS: In vitro metabolism of deoxycoformycin in human T lymphoblastoid cells. Phosphorylation of deoxycoformycin and incorporation into cellular DNA. J. Biol. Chem. 259, 9426-9433 (1984).
29. Malspeis L: Clinical pharmacokinetics of 2′-deoxycoformycin. Cancer Treatment Symposia 2, 7-15 (1984).
30. Matsumoto SS, Yu AL, Bleeker LC, Bakay B, Kung FH, Nyhan WL: Biochemical correlates of the differential sensitivity of subtypes of human leukemia to deoxyadenosine and deoxycoformycin. Blood 60, 1096-1102 (1982).
31. Russell NH, Carron J, Hoffbrand AV, Bellingham AJ: The relative sensitivity of peripheral blood T-lymphocyte colony forming cells and bone marrow CFU-GM to deoxyadenosine and 2′deoxycoformycin. Leuk. Res. 9, 315-319 (1985).
32. Petzer AL, Bilgeri R, Zilian U et al.: Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood 78, 2583-2587 (1991).
33. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU: Alpha interferon for induction of remission in hairy-cell leukemia. N. Engl. J. Med. 310, 15-18 (1984).
34. Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K: Treatment of hairy cell leukemia with recombinant alpha 2 interferon. Blood 65, 644-648 (1985).
35. Golomb HM, Jacobs A, Fefer A et al.: Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J. Clin. Oncol. 4, 900-905 (1986).
36. Ho AD, Thaler J. Mandelli F et al.: Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J. Clin. Oncol. 7, 1533-1538 (1989).
37. Grever M, Kopecky K, Foucar MK et al.: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J. Clin. Oncol. 13, 974-982 (1995).
38. Flinn IW, Kopecky KJ, Foucar MK et al.: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96, 2981-2986 (2000).
39. Goodman GR, Burian C, Koziol JA, Saven A: Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J. Clin. Oncol. 21, 891-896 (2003).
40. Flinn IW, Grever MR: Chronic lymphocytic leukemia. Cancer Treat Rev. 22, 1-13 (1996).
41. Rai KR, Peterson BL, Appelbaum FR er al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukema. N. Engl. J. Med. 343, 1750-1757 (2000).
42. Dillman RO, Mick R, McIntyre OR: Pentostatin in chronic lymphocytic leukemia: a Phase II trial of cancer and leukemia group B.J. Clin. Oncol. 7, 433-438 (1989).
43. Johnson S, Smith AG, Loffler H et al.: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347, 1432-1438 (1996).
44. Johnson SA, Catovsky D, Child JA, Newland AC, Milligan DW, Janmohamed R: Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest. New Drugs 16, 155-160 (1998).
45. Weiss MA, Maslak PG, Jurcic JG et al.: Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 21, 1278-1284 (2003).
46. Oken MM, Lee S, Kay NE, Knospe W, Cassileth PA: Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a Phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk. Lymphoma 45, 79-84 (2004).
47. Kay N, Geyer SM, Lin T: Combination chemotherapy with pentostatin cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia. Blood 104, 100a, (2004).
48. Duggan DB, Anderson JR, Dillman R, Case D, Gottlieb AJ: 2′ deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: a CALGB Phase II study. Med. Pediatr. Oncol. 18, 203-206 (1990).
49. Cummings FJ, Kim K. Neiman RS et. al.: Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J. Clin. Oncol. 9, 565-571 (1991).
50. Monfardini S, Sorio R, Cavalli F et al.: Pentostatin (2′-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: Phase II study of the EORTC Early Clinical Trials Group. Oncology 53, 163-168 (1996).
51. Drapkin R, Di Bella NJ, Faragher DC et al.: Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen. Clin. Lymphoma 4, 169-175 (2003).
52. Di Bella N, Reynolds C, Faragher D, Muscato J, Boehm KA, Asmar L: An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated. Stage III or IV, low-grade non-Hodgkin lymphoma. Cancer 103, 978-984 (2005).
53. Federico M. Callea V, Danesi R, Montanini A. Di Renzo N: Mitoxantrone, prednisone, pentostatin, and bleomycin for patients with indolent non-Hodgkin's lymphoma relapsed or unresponsive to previous treatments. Results of a phase of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (GISL). Cancer Ther. 1, 63-70 (2003).
54. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP: Diagnosis and management of Waldenstrom's macroglobulinemia. J. Clin. Oncol. 23, 1564-1577, (2005).
55. Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ: Fludarabine therapy in macroglobulinemic lymphoma. Blood 75, 1928-1931 (1990).
56. Dhodapkar MV, Jacobson JL, Gertz MA et al.: Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98, 41-48 (2001).
57. Leblond V, Levy V, Maloisel F et al.: Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 98, 2640-2644 (2001).
58. Fenchel K, Wijermans P, Mitrou PS, Hoelzer D, Bergmann L: Fludarabine is an effective agent in immunocytic lymphoma. Onkologie 17, 508-513 (1994).
59. Bjorkholm M, Celsing F, Runarsson G, Waldenstrom J: Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenstrom's macroglobulinemia. Int. J. Hematol. 62, 117-120 (1995).
60. Costa P, Luzzati R, Nicolato A et al.: Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenstrom's macroglobulinemia treated with fludarabine. Leuk. Lymphoma 28, 617-620 (1998).
61. Liu ES, Burian C. Miller WE, Saven A: Bolus administration of cladribine in the treatment of Waldenstrom macroglobulinaemia. Br. J. Haematol. 103, 690-695 (1998).
62. Bryson HM, Sorkin EM: Cladribine. A review of Its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 46, 872-894 (1993).
63. Riddell S, Johnston JB, Rayner HL, Israels LG: Response of Waldenstrom's macroglobulinemia to pentostatin (2′-deoxycoformycin). Cancer Treat. Rep. 70, 546-548 (1986).
64. Lamanna N, Kalaycio M, Maslak PG et al.: Pentostatin and cyclophosphamide with or without rituximab has significant activity in patients with previously treated chronic lymphocytic leukemia and other low grade lymphoid neoplasms. Blood 104 (2004).
65. Hensel M, Krasniqi F, Villabos M, Kornacker M, Ho AD: Pentostatin and cylcophosphamide followed by maintenance therapy with rituximab for previously treated patients with B-cell chronic lymphocytic leukaemia, and Walendstrom's macroglobulinemia. Blood 102, 404a, (2003).
66. Grever MR, Bisaccia E. Scarborough DA, Metz EN, Neidhart JA: An Investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 61, 279-282 (1983).
67. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D: The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol. 12, 2588-2593 (1994).
68. Greiner D, Olsen EA, Petroni G: Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 36, 950-955 (1997).
69. Ho AD, Suciu S, Stryckmans P et al.: Pentostatin in T-cell malignancies - a phase II trial of the EORTC Leukemia Cooperative Group. Ann. Oncol. 10, 1493-1498 (1999).
70. Kuzel TM, Hurria A, Samuelson E et al.: Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 87, 906-911 (1996).
71. Saven A. Piro LD: 2-chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies. Leuk. Lymphoma 10(Suppl.) 43-49 (1993).
72. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ: Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J. Natl Cancer Inst. 82, 1353-1355 (1990).
73. Kuzel TM, Roenigk HH Jr, Samuelson E et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin. Oncol. 13, 257-263 (1995).
74. Enblad G, Hagberg H, Erlanson M et al.: A pilot study of alemtuzumab (anti-CD52 monocional antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103, 2920-2924 (2004).
75. Foss FM, Borkowski TA, Gilliom M et aL.: Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 84, 1765-1774 (1994).
76. LeMaistre CF, Meneghetti C, Rosenblum M et al.: Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB4861L-2) in hematologic malignancies expressing the IL-2 receptor. Blood 79, 2547-2554 (1992).
77. Johnston JB, Eisenhauer E, Corbett WE, Scott JG, Zaentz SD: Efficacy of 2′-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J. Natl Cancer Inst. 80, 765-769 (1988).
78. Kraut EH, Bouroncle BA, Grever MR: Pentostatin in the treatment of advanced hairy cell leukemia. J. Clin. Oncol. 7, 168-172 (1989).
79. Cassileth PA,Cheuvart B, Spiers AS et al.: Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol. 9, 243-246 (1991).
80. Golomb HM, Dodge R, Mick R et al.: Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALB study (8515). Leukemia 8, 2037-2040 (1994).
81. Reynolds C, Di Bella N, Drapkin R, Murali M, Boehm KA: Results of an open-label, pilot study of pentostain rituximab, and cyclophosphamide, in the treatment of patients with previously untreated chronic lymphocytic leukemia. Blood 102, 5155, (2003).
82. Weiss MA, Lamanna N, Kalaycio M et al.: Pentostatin and cyclophosphamide compared to pentostatin, cyclophosphamide, and rituximab as salvage therapy for patients with chronic lymphocytic leukemia. J. Clin. Oncol. 22, 6568 (2004).
83. Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD: Pentostatin/ cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin. Lymphoma Myeloma 6, 131-135 (2005).
84. Wierda W, O'Brien S, Wen S et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4070-4078 (2005).
85. Keating MJ, O'Brien S, Albitar M et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4079-4088 (2005).
86. Robak T, Blonski J, Gora-Tybor J et al.: Alone or in combination with cyclophosphamide or cyclophosphamide and mitoxantrone as first line treatment in chronic lymphocytic leukemia: an early report of prospective randomized study. Blood 104, 337 (2004).
87. Hensel M, Krasniqi F, Villalobos M, Kornacker M, Ho AD: Pentostatin, cyclophosphamide and rituximab is an active regimen with low toxicity for previously treated patients with B-cell chronic lymphocytic leukemia and Waidenström's macroglobulinemia. J. Clin. Oncol. 22, 6557 (2004).
88. Dearden C, Matutes E, Catovsky D: Deoxycoformycin in the treatment of mature T-cell leukaemias. Br. J. Cancer 64, 903-906 (1991).
89. Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J. Clin. Oncol. 17, 3117-3121 (1999).
90. Foss FM, Ihde DC, Breneman DL et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J. Clin. Oncol. 10, 1907-1913 (1992).
91. Matutes E, Brito-Babapulle V, Swansbury J et al.: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78, 3269-3274 (1991).
92. Dohner H, Ho AD, Thaler J et al.: Pentostatin in prolymphocytic leukemia: Phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J. Natl Cancer Inst. 85, 658-662 (1993).